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with the introduction of generic lovastatin, atorvastatin
was launched and appeared to benefit from the decline in
A&P of lovastatin, as did pravastatin.
CONCLUSION: Evidence exists in each of the three mar-
kets reviewed to support the hypothesis for two of the
three therapeutic classes investigated. There appeared to be
a trend toward a significant increase in growth in competi-
tive branded compounds in both the SSRI and statin mar-
kets following introduction of the first generic drug.
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OBJECTIVE: Responsiveness has been pointed out by
the WHO as one of the main objectives for any health
system. Portugal, despite being in the expected place
among other countries and taking into account the level
of health of its citizens and the level of cultural and eco-
nomic development, is placed very low when responsive-
ness is considered. This study aimed at assessing the per-
ceptions of Portuguese citizens as users of primary care.
METHODS: A representative sample of users of all
health centers within an entire health region was asked
about how responsive primary care was. Users’ satisfac-
tion was measured via the Portuguese version of the
Europep questionnaire. This instrument mainly measures
relationship and communication, medical care, informa-
tion and support, continuity and cooperation, and service
organization. Four thousand answers were received
(40.5% response rate) from a survey performed in major
urban and rural areas.
RESULTS: 62% of users were female with an average
age of 47 years, 50% with low or very low education and
with an average of 5.2 visits per year. Approximately
12% felt a good or excellent quality of life and 71%
mentioned having a chronic disease. The results indicated
a higher satisfaction from users about the doctor-patient
relationship, both in caring (76%) and curing (70%) as-
pects. The areas related to the organization were, how-
ever, very penalized by patients (49%). Open-ended
questions revealed the same profile but provided greater
insight about the source of the dissatisfaction. The results
were also compared taking into account gender, age, edu-
cation and quality of life.
CONCLUSION: Paraphrasing Deming, it is common to
observe a majority of areas of concern among the organi-
zation’s management and administration. Health-care
setting is not an exception. After this diagnosis, based on
patients’ views, it is advised to look with more attention
at these aspects.
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OBJECTIVE: To derive one European EQ-5D value set
that can be used to calculate a European EQ-5D health-
status index based on preferences of the general public.
EQ-5D from the EuroQol Group is an instrument capa-
ble of summarizing health-related quality of life into a
single index value by applying general population prefer-
ence weights. Values have been derived for EQ-5D health
states using the visual analogue scale (VAS) or time trade-
off (TTO) approaches. The option to derive European
VAS- and TTO-based EQ-5D health status models has
been investigated.
METHODS: Multi-level analysis was performed on
82,910 observations of VAS values derived from 11 stud-
ies in different countries and on 50,780 TTO observa-
tions derived from three studies.
RESULTS: After controlling for background variables, it
was found that the country of origin of the study did not
have a consistent effect on the VAS valuations of the
EQ-5D health states. The evidence shows that European
countries may share a similar value system for VAS rat-
ings of health states. All coefficients have the right signs,
while the values all differ from zero and produce values
that are plausible. The explained variance by the model
describing VAS values is 74.5 %. Multilevel analysis of
the TTO valuations revealed that on average the German
values are 20 % higher than the English and Spanish val-
ues. Half of this difference can be explained by control-
ling for background variables.
CONCLUSIONS: These results suggest that while more
work is required to establish a European TTO-based
health-status index, a European VAS-based EQ-5D health-
status index is viable. A European health-status index
has two advantages: i) An index would not have to be
generated separately for each European country, and ii)
the index can be used in multi-national randomized clini-
cal trials examining cost effectiveness of pharmaceutical
products.
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OBJECTIVE: To assess the number and type of pharma-
ceutical interventions for medical wards during the initial
three-month period of a new clinical pharmacy service.
METHODS: The clinical pharmacist participated in daily
rounds and other ward activities to review patient data
and determine necessary interventions. A computerized
evaluation and intervention form was developed to in-
clude patients’ demographic details, diagnoses, labora-
tory results, medication use and the reason for the inter-
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vention. The main intervention areas were: adverse drug
effects; incorrect dosage; polypharmacy, and drug-drug,
drug-disease and drug-food interactions. Based on this
data, the pharmacist suggested specific changes in drug
treatment including route of administration, changing
dosing, eliminating drug interactions and preventing life-
threatening drug combinations. In addition the clinical
pharmacist provides pharmaceutical information to phy-
sicians and nursing staff.
RESULTS: We reviewed approximately 2300 medical
records and found one or more interventions in 11% of
the cases. The main type of interventions were: 99
(38.9%) unnecessary drugs; 51 (20%) incorrect dose; 47
(18.5%) drug information; 26 (10.2%) adverse drug re-
action; 17 (6.6%) drug-drug interactions, and 14 (5.5%)
therapeutic drug monitoring. It should be emphasized
that 112 drug interactions with varying degrees of sever-
ity were prevented. The physicians, in 96% of all inter-
ventions, accepted the clinical pharmacist’s recommenda-
tions.
CONCLUSION: The results demonstrate that the clinical
pharmacist contributes substantially to the quality of pa-
tient care involving drug-related problems. In addition,
this intervention may reduce length of hospital stay and
lower drug costs.
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OBJECTIVE: To estimate the in-hospital costs of blood
products in German hospitals.
METHODS: Data on personnel-time and material-resource
utilisation associated with blood products were collected
as part of a health-economic study on hospital costs for
Coronary Artery Bypass Graft patients with and without
rethoracotomy in Germany. The real cost to hospitals for
blood products was then calculated based on these data.
The transfusion departments in four hospitals each com-
pleted a questionnaire, giving details of materials and time
required to obtain or to prepare erythrocytes (autologous
and homologous blood) and autologous fresh frozen
plasma. Hospital administration departments provided in-
formation from which personnel costs were calculated.
RESULTS: For homologous erythrocytes, total costs
were 194 DM (99 Euro) per unit of donor red blood
cells. Logistics, testing and materials (e.g. use of transfu-
sion instruments) amounted to a total of 77 DM (39
Euro) in addition to the acquisition costs. On average,
about 50 minutes were spent on ordering, buying, stor-
age, administration, disposal and testing of the banked
blood. The production of one unit from autologous
blood cost 223 DM (114 Euro). Time taken by staff
made up a significant portion of these costs. On average,
130 minutes were necessary for collection of blood, prep-
aration, testing, storage, administration, disposal and re-
testing before the operation. Fresh frozen plasma was ob-
tained during preparation of autologous blood and cost
an extra 31 DM (16 Euro) per unit.
CONCLUSION: This economic analysis of blood prod-
ucts shows that both personnel and material costs for ad-
ditional processing of blood products amount to a signif-
icant part of the total hospital costs. Blood-product
acquisition costs alone may lead to an underestimation of
the economic benefit associated with treatments that po-
tentially reduce the need for blood products.
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OBJECTIVES: To estimate the number of patients and
costs for the treatment of selected diseases in Switzerland,
depending on physical activity level. Calculation of acci-
dents due to sport or other causes.
METHODS: Top-down approach, modeling the number
of cases and deaths due to coronary heart disease (CHD),
hypertension, non-insulin-dependent diabetes (NIDD),
mammary cancer, colon cancer, lower back pain (LBP),
brief recurrent depression, osteoporosis. Distinction by
activity level (active or not). Decision tree model for cal-
culating the number of accidents, disability, and deaths
due to sports and general accidents. Inclusion of direct
costs, indirect costs, and transfer payments. A compari-
son of disease and accident costs was not possible, be-
cause accidents could not be separated by activity level.
RESULTS: The burden of disease is 8.5 billion SFr in di-
rect and 6 billion SFr in indirect costs. The inactive popu-
lation (37%) incurs most of the direct costs (49%, 4.14
billion SFr). Diseases occurring in the active population
(61%) require 2.7 billion SFr a year. Each physically in-
active person costs 2595 SFr per year; active people,
1700 SFr per year. The risks attributable to physical inac-
tivity are: CHD, 24%; hypertension, 15%; NIDD, 24%;
mammary cancer, 12%; colon cancer, 25%; LBP, 12%;
depression, 44%; osteoporosis, 27%. The proportion of
costs for diseases caused by physical inactivity is 16%.
Total number of general accidents is 670,000, plus
299,000 sports-related accidents. 1875 accident-related
deaths occur, with only 161 (9%) of them caused by
sport. The ratio of the yearly direct costs of non-sport/
sport-related accidents is 3.4 / 1.1 billion SFr, and the ra-
